| Title |
Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete Athymia
|
|---|---|
| Published in |
Frontiers in immunology, January 2013
|
| DOI | 10.3389/fimmu.2013.00322 |
| Pubmed ID | |
| Authors |
E. Graham Davies |
| Abstract |
The commonest association of thymic stromal deficiency resulting in T-cell immunodeficiency is the DiGeorge syndrome (DGS). This results from abnormal development of the third and fourth pharyngeal arches and is most commonly associated with a microdeletion at chromosome 22q11 though other genetic and non-genetic causes have been described. The immunological competence of affected individuals is highly variable, ranging from normal to a severe combined immunodeficiency when there is complete athymia. In the most severe group, correction of the immunodeficiency can be achieved using thymus allografts which can support thymopoiesis even in the absence of donor-recipient matching at the major histocompatibility loci. This review focuses on the causes of DGS, the immunological features of the disorder, and the approaches to correction of the immunodeficiency including the use of thymus transplantation. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Unknown | 125 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 23 | 18% |
| Student > Ph. D. Student | 17 | 13% |
| Student > Master | 17 | 13% |
| Other | 12 | 9% |
| Researcher | 12 | 9% |
| Other | 26 | 20% |
| Unknown | 20 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 43% |
| Agricultural and Biological Sciences | 17 | 13% |
| Biochemistry, Genetics and Molecular Biology | 14 | 11% |
| Immunology and Microbiology | 10 | 8% |
| Engineering | 2 | 2% |
| Other | 9 | 7% |
| Unknown | 21 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2016.
All research outputs
#15,739,529
of 25,374,647 outputs
Outputs from Frontiers in immunology
#15,375
of 31,516 outputs
Outputs of similar age
#177,361
of 288,991 outputs
Outputs of similar age from Frontiers in immunology
#162
of 503 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 31,516 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,991 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 503 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.